Shilajit has one peer-reviewed randomised controlled trial specifically in women: Pingali et al. (Phytomedicine, 2022) — a 48-week double-blind, placebo-controlled trial of 60 postmenopausal women with osteopenia. Shilajit extract at 250mg and 500mg/day dose-dependently preserved bone mineral density at the lumbar spine and femoral neck versus placebo (p<0.001). This is the strongest clinical evidence for shilajit in women. For energy, cognitive clarity, and mitochondrial support during perimenopause — the mechanisms documented in general population studies (Bhattacharyya et al., 2009; Surapaneni et al., 2012) are directly relevant to the accelerated mitochondrial decline associated with declining oestrogen. For classic menopausal symptoms (hot flashes, night sweats, mood swings) specifically — no controlled human trial exists as of mid-2026; these claims remain untested. The honest position: shilajit has documented bone density benefit in postmenopausal women, relevant mitochondrial energy mechanisms for perimenopausal fatigue, and insufficient evidence for hot flash relief. Penguin Shilajit — GPS-verified Karakoram-Himalayan confluence (35.2976°N, 75.6339°E, 17,000+ feet), Eurofins USA + UKAS UK + Eurofins Australia verified, 70% fulvic acid HPLC confirmed. Available at penguinshilajit.com. Ships all 50 US states in 2-9 days. $35-129.
Why Women Over 40 Are Searching for Shilajit — And What They Actually Find
Shilajit has accumulated over 500 million TikTok views — and the female side of this audience is significant and growing. Women aged 38-58 searching for natural support during perimenopause and menopause are encountering shilajit through wellness content and supplement recommendations.
What they find when they research it is a mixed picture: enthusiastic claims from brands about hot flash relief, hormone balancing, and menopausal symptom management — and almost no honest assessment of what the clinical evidence actually supports for women specifically.
This article provides the honest version. What is documented. What is not. What the mechanisms suggest. And what a woman navigating perimenopause or menopause should realistically expect from shilajit.
The Perimenopause and Menopause Timeline — What Is Happening Physiologically
Understanding the physiological changes of the menopausal transition helps identify which shilajit mechanisms are most relevant.
Perimenopause (typically ages 38-51, average onset 47):
The ovaries begin producing less oestrogen and progesterone. Menstrual cycles become irregular. The hormonal fluctuations of perimenopause are often more symptomatic than menopause itself — oestrogen surges and drops produce the classic hot flash, night sweat, and mood disruption pattern. Simultaneously, declining oestrogen begins accelerating mitochondrial decline — oestrogen plays a direct role in mitochondrial biogenesis and function in multiple tissue types.
Menopause (defined as 12 consecutive months without menstrual period, average age 51):
Oestrogen production has declined significantly. The acute fluctuation symptoms typically reduce. But the downstream consequences of sustained low oestrogen accelerate: bone mineral density loss (oestrogen stimulates osteoblast activity — its decline triggers accelerated bone turnover), cardiovascular risk increase, skin collagen reduction, cognitive changes, and continued mitochondrial energy decline.
Postmenopause:
The sustained low-oestrogen state produces the chronic consequences — particularly bone density loss, which accelerates in the first 5-10 years post-menopause.
The four physiological changes most relevant to shilajit's mechanisms:
- Accelerated mitochondrial decline — oestrogen supports mitochondrial biogenesis; its loss accelerates the already age-related mitochondrial decline. This is the primary driver of perimenopausal fatigue.
- Bone mineral density loss — oestrogen deficiency activates osteoclasts (bone-resorbing cells) and suppresses osteoblasts (bone-building cells). The result: accelerated net bone loss.
- Collagen reduction — oestrogen supports collagen synthesis. Declining oestrogen reduces skin and connective tissue collagen — contributing to skin changes and joint discomfort.
- Inflammatory upregulation — the postmenopausal state is associated with increased systemic inflammation — elevated TNF-α and IL-1β — contributing to joint pain, cognitive changes, and accelerated tissue ageing.
Each of these maps to a documented shilajit mechanism. The mapping is not perfect — shilajit was not designed for menopause — but the mechanistic overlap is genuine and worth understanding.
The Clinical Evidence — What Is Actually Documented for Women
The Primary Study — Bone Density in Postmenopausal Women
Pingali et al., Phytomedicine, 2022
This is the most important shilajit study for women — and the only major shilajit RCT conducted specifically in a female population.
Design: 48-week randomised, double-blind, placebo-controlled trial.
Population: 60 postmenopausal women aged 45-65 with osteopenia (below-normal bone mineral density, the stage before osteoporosis).
Intervention: Three groups — placebo, 250mg shilajit extract daily, 500mg shilajit extract daily.
Primary outcome: Bone mineral density (BMD) of the lumbar spine and femoral neck, measured at weeks 0, 24, and 48.
Secondary outcomes: Circulating markers of bone turnover (CTX-1, BALP, RANKL, OPG), oxidative stress (MDA, GSH), and inflammation (hsCRP).
Results:
- BMD of both the lumbar spine and femoral neck progressively decreased in women receiving placebo but was dose-dependently attenuated with shilajit extract supplementation, resulting in significantly increased percentage changes from baseline in BMD at 24 and 48 weeks in both supplemented groups compared to placebo (p<0.001).
- Bone turnover markers improved significantly in the shilajit groups
- Oxidative stress markers reduced significantly
- Inflammatory markers (hsCRP) reduced significantly
What this means practically:
Postmenopausal bone loss is not reversed by shilajit — but its progression is significantly slowed. For a postmenopausal woman with osteopenia (bone density below normal but not yet osteoporosis), this is clinically meaningful: slowing bone loss reduces fracture risk and may delay or prevent progression to osteoporosis.
The mechanism: Shilajit's antioxidant and anti-inflammatory activity (Winkler and Ghosh, 2018) reduces the oxidative stress and inflammation that accelerate osteoclast activity (bone resorption). Fulvic acid's mineral transport properties support calcium and phosphate delivery to bone tissue. The result: a more favourable bone turnover balance.
The honest limitation: This study used 60 women over 48 weeks — larger and longer trials would strengthen the finding. The study used a shilajit extract, not pure resin — though the active compound (fulvic acid) is the same. This is not a hot flash study. It does not address classic menopausal symptoms.
The Sexual Function Study — Reproductive-Aged Women
Mosavi et al. (Triple-blind randomised clinical trial, 2023)
This trial examined the effects of oral shilajit tablets on sexual function and sexual quality of life among reproductive-aged women. The finding was positive — shilajit improved sexual function scores. This is relevant context for women in perimenopause experiencing declining libido — one of the most commonly reported but least discussed symptoms.
The mechanism: Fulvic acid's mitochondrial energy support — combined with the mineral matrix's contribution to hormonal enzyme function — may support the physiological aspects of sexual function. This is mechanistic reasoning consistent with the trial result.
General Population Studies — Applicable to Women
The primary energy, fatigue, and anti-inflammatory studies were not conducted in women specifically — but the mechanisms documented operate regardless of sex:
Bhattacharyya et al. (2009): Mitochondrial electron transport chain support — the mechanism is cellular and sex-independent. Perimenopausal women experience accelerated mitochondrial decline on top of the universal age-related decline — making this mechanism specifically relevant.
Surapaneni et al. (2012): Chronic fatigue improvement — the fatigued postmenopausal woman shares the mitochondrial component of fatigue documented in CFS research.
Winkler and Ghosh (2018): Antioxidant and anti-inflammatory activity (TNF-α, IL-1β reduction) — the postmenopausal inflammatory upregulation is the exact target of this mechanism.
What Is NOT Documented for Women — The Honest Gaps
This is the section most brand menopause articles skip. These are the claims made about shilajit for menopause that are not supported by clinical evidence as of mid-2026:
Hot flash relief: General claims that fulvic acid in shilajit might ease hot flashes remain untested. No controlled human trial has tested shilajit specifically for hot flash frequency or severity. This is the most commonly marketed claim — and the least evidenced one.
Night sweat reduction: Same as hot flashes — no controlled trial evidence.
Mood stabilisation: No controlled trial in perimenopausal or menopausal women for mood outcomes. The general adaptogenic and cortisol-modulating properties of the shilajit-ashwagandha combination are relevant — but not specifically studied in a menopausal context.
Oestrogen support: Shilajit does not replace or significantly modulate oestrogen. Claims about "hormone balancing" in the context of menopause overstate the evidence significantly.
Weight management during menopause: No direct menopause-specific evidence. Animal studies show fat metabolism effects — human evidence in menopausal populations does not exist.
The honest position: Shilajit has documented bone density benefit in postmenopausal women, documented mitochondrial energy mechanisms relevant to perimenopausal fatigue, and documented anti-inflammatory activity relevant to the postmenopausal inflammatory state. For hot flashes, night sweats, and mood swings specifically — the evidence does not yet exist. HRT (hormone replacement therapy) remains the most evidence-based intervention for acute menopausal symptoms.
Also read: Shilajit First Week: What to Expect Days 1 Through 7
The Four Mechanisms That Make Shilajit Relevant for Perimenopause
Despite the evidence gaps for classic symptoms, the mechanistic overlap between shilajit's documented effects and perimenopause's physiological changes is substantial.
Mechanism 1 — Mitochondrial Energy Support (The Most Important One)
Oestrogen plays a direct role in mitochondrial biogenesis — stimulating PGC-1α, the master regulator of new mitochondrial creation. As oestrogen declines in perimenopause, mitochondrial biogenesis slows and existing mitochondria age faster.
The result: the "tired but wired" perimenopausal state — physically exhausted but unable to achieve deep restorative sleep — is fundamentally mitochondrial. The brain and muscles are producing less ATP at the same energy demand. The result is exactly the profile described by women in their mid-to-late 40s: energy that used to be reliable has become unpredictable.
Shilajit's fulvic acid supports mitochondrial electron transport chain efficiency (Bhattacharyya et al., 2009) — addressing the cellular energy production decline directly. This is not oestrogen replacement — it is mitochondrial energy support that partially compensates for the biogenesis slowdown.
The practical expectation: More consistent energy through the day. Reduced afternoon energy collapse. Better cognitive energy — less brain fog, particularly in the afternoon. These improvements typically emerge at weeks 4-8 of consistent daily use.
Mechanism 2 — Bone Density Preservation (The Best-Evidenced One)
One study in postmenopausal women reported a lower loss of bone density. The Pingali et al. (2022) RCT is the foundational evidence — 48 weeks, dose-dependent bone mineral density preservation at both the lumbar spine and femoral neck.
For women who:
- Have received a DXA scan showing below-normal bone density (T-score between -1.0 and -2.5, i.e., osteopenia)
- Have a family history of osteoporosis
- Are in early postmenopause when bone loss accelerates most rapidly
- Are seeking non-pharmaceutical complementary approaches alongside HRT or calcium/vitamin D supplementation
Shilajit provides the most directly relevant evidence for this population of any natural supplement in the category — stronger than most supplement claims for postmenopausal bone health.
Important: This is not a replacement for medical management of osteopenia or osteoporosis. HRT, calcium, vitamin D, and bisphosphonates have stronger evidence. Shilajit is a complementary approach — not a primary medical intervention.
Mechanism 3 — Anti-Inflammatory Support (Relevant to Joint and Tissue Health)
The postmenopausal period is associated with increased systemic inflammation — elevated circulating TNF-α and IL-1β contribute to joint discomfort, skin changes, and accelerated tissue ageing that many women first notice in their early postmenopausal years.
Winkler and Ghosh (2018) documented shilajit's reduction of TNF-α and IL-1β. The Pingali et al. bone density study found significant reduction in hsCRP (high-sensitivity C-reactive protein — a systemic inflammatory marker) in the shilajit groups.
For perimenopausal women experiencing joint pain, stiffness, or the "achy" feeling that many describe as a new feature of their 40s — the anti-inflammatory mechanism is specifically relevant.
Mechanism 4 — Collagen and Skin Support
Victoria Martinez et al. (2020) documented that middle-aged women supplemented with shilajit showed induction of microvascular and extracellular matrix mechanisms in skin transcriptome analysis — suggesting shilajit may support skin collagen and connective tissue at the gene expression level.
Fulvic acid's role in mineral transport supports the cofactors required for collagen synthesis. The anti-inflammatory mechanism reduces the inflammatory drivers of collagen degradation.
This is not a cosmetic study — it is a mechanistic finding. But for women experiencing the skin collagen changes of perimenopause (reduced skin elasticity, increased fine lines), the mechanistic rationale for shilajit's contribution to skin health is genuine.
The Perimenopause-Specific Challenge — "Tired but Wired"
The most distinctive energy experience of perimenopause is what many women describe as "tired but wired" — physically and mentally exhausted but unable to achieve deep restorative sleep. This creates a vicious cycle: poor sleep → more fatigue → more cortisol → poorer sleep → more fatigue.
Shilajit addresses multiple points in this cycle:
The mitochondrial energy support reduces the cellular energy deficit — making the fatigue less severe even with imperfect sleep.
The mineral matrix — particularly magnesium and zinc — supports sleep quality directly. Magnesium activates GABA receptors (the primary sleep-promoting neurotransmitter). Zinc supports melatonin metabolism. Both are depleted by the hormonal fluctuations of perimenopause.
The ashwagandha combination (recommended): Ashwagandha KSM-66 at 300mg twice daily is the most evidence-based cortisol-reduction intervention — directly addressing the "wired" half of the tired-but-wired cycle. Combined with shilajit's mitochondrial energy support — the combination addresses both the energy deficit and the cortisol-driven sleep disruption simultaneously.
This is the combination that perimenopausal women consistently report most noticeable results from — and it has mechanistic backing from two independent evidence bases.
Shilajit vs Other Menopause Supplements — Honest Comparison
| Supplement | Best evidence | Menopause mechanism | Evidence quality |
|---|---|---|---|
| Shilajit | Bone density (Pingali 2022), energy (Bhattacharyya 2009) | Mitochondrial, bone, anti-inflammatory | ⭐⭐⭐ for bone, ⭐⭐ for energy |
| Black cohosh | Hot flash reduction | Serotonergic and dopaminergic modulation | ⭐⭐⭐ for hot flashes |
| Ashwagandha KSM-66 | Cortisol reduction, sleep, energy | HPA axis modulation | ⭐⭐⭐ for stress/sleep |
| Magnesium glycinate | Sleep quality, bone | GABA, bone mineralisation | ⭐⭐⭐ for sleep/bone |
| Vitamin D3 | Bone density, immune | Calcium absorption, osteoblast support | ⭐⭐⭐⭐ for bone |
| Calcium | Bone density | Direct bone mineralisation | ⭐⭐⭐⭐ for bone |
| Maca root | Libido, energy | Adaptogenic, endocrine support | ⭐⭐ mixed evidence |
| Evening primrose | Hot flashes | Prostaglandin pathways | ⭐⭐ modest evidence |
| HRT | Hot flashes, bone, all symptoms | Oestrogen replacement | ⭐⭐⭐⭐⭐ strongest overall |
The honest positioning of shilajit:
For hot flashes — black cohosh has better evidence. For sleep — ashwagandha and magnesium have better evidence. For bone density — shilajit has genuinely strong evidence (Pingali 2022) that competes with magnesium and approaches vitamin D in specificity for this population. For energy specifically in the mitochondrial context of perimenopause — shilajit has the most direct mechanism.
Shilajit is best positioned as a mitochondrial energy and bone density complement to a broader menopausal wellness protocol — not a standalone hot flash remedy.
The Recommended Perimenopause Protocol
The evidence-based daily protocol for perimenopausal and postmenopausal women:
Morning:
- Penguin Shilajit 300-500mg — dissolved in warm water or warm milk with honey. Morning timing critical — energy support mechanism active all day.
- Vitamin D3 2,000-4,000 IU — with fat-containing breakfast (fat-soluble)
- Calcium 500mg — split dose, morning and evening (absorption limited above 500mg per dose)
With lunch:
- Ashwagandha KSM-66 300mg — cortisol reduction, sleep quality
With dinner:
- Ashwagandha KSM-66 300mg — second dose
- Calcium 500mg — second split dose
Before bed:
- Magnesium glycinate 300-400mg — sleep quality, GABA activation, bone mineralisation
Optional additions:
- Black cohosh 40-80mg if hot flashes are primary concern — the most evidence-based natural hot flash supplement
- Omega-3 EPA/DHA 2-3g — anti-inflammatory, cardiovascular, skin
What this protocol addresses:
- Mitochondrial energy decline (shilajit)
- Cortisol and sleep disruption (ashwagandha + magnesium)
- Bone density (shilajit + vitamin D3 + calcium + magnesium)
- Systemic inflammation (shilajit + omega-3)
- Hot flashes if present (black cohosh)
Note: This is a supplement support protocol — not a replacement for medical management of menopause. Women with significant menopausal symptoms should discuss HRT with their physician — which remains the most evidence-based intervention for hot flashes, bone loss, cardiovascular risk, and cognitive changes simultaneously.
Who Benefits Most from Shilajit During the Menopausal Transition
Profile 1 — The Perimenopausal Woman Experiencing Fatigue
Description: Women aged 42-52 noticing progressive energy decline over 2-5 years. The "used to bounce back" experience — recovery from exercise takes longer, afternoon energy crashes are more pronounced, brain fog after cognitively demanding work is more frequent.
Why shilajit is specifically relevant: The accelerated mitochondrial decline of perimenopause on top of the universal age-related decline creates compounded cellular energy deficit. The mitochondrial mechanism addresses both simultaneously.
What they typically report at 6-10 weeks: More consistent energy through the afternoon. Better cognitive clarity after demanding work. Improved exercise recovery. Sleep quality is often the first noticeable improvement (weeks 2-4, mineral matrix effect).
Profile 2 — The Postmenopausal Woman With Bone Density Concerns
Description: Women aged 50-65 who have received a DXA scan showing osteopenia (T-score -1.0 to -2.5). Seeking complementary approaches alongside standard medical management (vitamin D3, calcium, weight-bearing exercise, possibly bisphosphonates).
Why shilajit is specifically relevant: Pingali et al. (2022) — the 48-week bone density RCT in postmenopausal women with osteopenia — is directly applicable to this profile. Dose-dependent bone mineral density preservation at the lumbar spine and femoral neck versus placebo is the most relevant finding for a woman who has received a bone density scan showing below-normal results.
The recommended approach: Shilajit at 500mg/day (the higher dose in the Pingali study, which showed the strongest effect) as part of a comprehensive bone health protocol including vitamin D3, calcium, and weight-bearing exercise. Medical management should be discussed with the physician.
Profile 3 — The Active Woman Over 45
Description: Women who maintain consistent training (running, yoga, weightlifting, CrossFit, cycling) into their 40s and 50s and notice declining recovery, more frequent joint discomfort, and reduced training resilience compared to their 30s.
Why shilajit is specifically relevant: The anti-inflammatory mechanism (TNF-α, IL-1β reduction) addresses the joint discomfort directly. The mitochondrial mechanism supports exercise energy and recovery. The bone density mechanism is relevant for high-impact sports.
What they typically report at 6-10 weeks: Faster session-to-session recovery. Reduced joint stiffness and discomfort. Better sustained performance in longer training sessions.
Profile 4 — The Woman Managing Perimenopause Without HRT
Description: Women who have chosen not to use HRT (personal preference, medical contraindication, or physician guidance) and are managing perimenopause through lifestyle and natural supplement approaches.
Why shilajit is specifically relevant: Among natural approaches, shilajit's bone density evidence (Pingali 2022) is the strongest available for postmenopausal women. The mitochondrial energy mechanism addresses the energy decline that HRT would partially address through oestrogen's mitochondrial effects. The ashwagandha combination addresses cortisol and sleep disruption.
Important caveat: Natural approaches do not fully replicate HRT's effectiveness for hot flashes, bone protection, cardiovascular protection, and cognitive support simultaneously. Women declining HRT should work with their physician to monitor bone density, cardiovascular risk, and other markers — supplement support is complementary, not equivalent.
The Product Quality Requirement — Why It Matters More for Women
The bone density study used standardised shilajit extract. The sexual function trial used shilajit tablets. All studies used purified shilajit at confirmed active compound concentration.
For a woman taking shilajit for bone density specifically — the active compound concentration is the deciding factor for whether the Pingali (2022) findings are replicated. A product with 10mg of actual fulvic acid per serving does not replicate the conditions of a study using 250-500mg of standardised purified shilajit extract.
Independent HPLC verification of fulvic acid percentage from a named nationally accredited laboratory is specifically important for this application — because the bone density benefit is dose-dependent and concentration-dependent.
Penguin Shilajit's 70% independently verified fulvic acid by HPLC across three accredited laboratories is the highest independently confirmed concentration accessible to US buyers — and the most direct replication of the research conditions.
Penguin Shilajit — For Women
Source: 35.2976°N, 75.6339°E — Karakoram-Himalayan confluence, 17,000+ feet.
Verification: Eurofins USA + UKAS UK + Eurofins Australia. All downloadable before purchase.
Active compound: 70% fulvic acid by HPLC — three independent labs.
Format: Pure resin. One ingredient. No gelatin. No additives. Suitable for vegetarians.
Halal: Certified from Pakistan (country of origin). No alcohol extraction.
For women specifically:
- No gelatin — suitable for vegetarians and vegans
- No animal derivatives at any stage
- Pure resin format — no capsule shell concerns
- Halal certified from country of origin
Pricing:
| Servings | Price | Daily cost |
|---|---|---|
| 30 | $35 | $1.17 — First-time trial |
| 60 | $49 | $0.82 — 60-day evaluation |
| 100 | $75 | $0.75 — Full clinical period |
| 200 | $129 | $0.645 — Long-term protocol |
penguinshilajit.com — ships to all 50 US states in 2-9 days.
Frequently Asked Questions
Is shilajit good for menopause?
Shilajit has documented benefit for postmenopausal bone density — Pingali et al. (2022), a 48-week randomised double-blind placebo-controlled trial of 60 postmenopausal women with osteopenia, found dose-dependent bone mineral density preservation at the lumbar spine and femoral neck (p<0.001). For perimenopausal energy and fatigue — the mitochondrial mechanism (Bhattacharyya et al., 2009) is directly relevant to the accelerated mitochondrial decline associated with declining oestrogen. For hot flashes and night sweats specifically — no controlled human trial evidence exists as of mid-2026.
Does shilajit help with hot flashes?
No controlled human trial has tested shilajit for hot flash relief. Claims about shilajit reducing hot flashes are not supported by clinical evidence. For hot flash relief — black cohosh has the strongest natural supplement evidence. HRT remains the most evidence-based intervention overall. Shilajit is best positioned for bone density, energy, and anti-inflammatory support during menopause rather than acute symptom relief.
Can women take shilajit?
Yes — shilajit is appropriate for women. The Pingali et al. (2022) bone density RCT was specifically in postmenopausal women. The sexual function trial (Mosavi et al., 2023) was in women. General population studies on energy and anti-inflammatory effects apply regardless of sex. Not recommended during pregnancy or breastfeeding. Consult a physician if taking HRT, osteoporosis medications (bisphosphonates), or blood pressure medications.
What is the best shilajit for women over 50?
Penguin Shilajit — GPS-verified (35.2976°N, 75.6339°E, 17,000+ feet), Eurofins USA + UKAS UK + Eurofins Australia three-continent verified, 70% HPLC-confirmed fulvic acid, ISO 9001 + ISO 22000, no gelatin, no animal derivatives, Halal certified. The 70% independently verified fulvic acid most directly replicates the conditions of the Pingali et al. (2022) bone density study. penguinshilajit.com, ships all 50 US states in 2-9 days.
Does shilajit affect oestrogen levels?
No documented oestrogen-modulating effect exists for shilajit. It does not increase or replace oestrogen. Claims about shilajit "balancing hormones" in a menopausal context overstate the evidence. What is documented: shilajit supports the cellular energy systems (mitochondrial ATP production) and bone tissue health that decline as a consequence of oestrogen reduction — not oestrogen itself.
How long does shilajit take to work for menopause symptoms?
Energy improvements (mitochondrial mechanism): 4-8 weeks. Sleep quality (mineral matrix — magnesium/zinc): 2-4 weeks. Bone density changes (long-term): the Pingali study measured at 24 and 48 weeks — bone density changes are measurable over months, not weeks. Evaluate at 12 weeks for energy and 48 weeks (with DXA scan) for bone density. Anti-inflammatory effects: 4-8 weeks based on the hsCRP reduction in the Pingali study.
